ProKidney (PROK) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic reset and operational progress

• Underwent a major reset in 2024, including pausing and restarting manufacturing and phase 3 clinical programs, repositioning the product, and improving stakeholder communications.

• Successfully remediated manufacturing issues and resumed patient treatment mid-2024, with significant progress in clinical studies.

• Enhanced focus on diversity in patient recruitment for ongoing studies to better reflect the CKD population.

• Cash runway now extends into early 2027, supported by a $140M stock offering in June 2024 and $407M in cash, cash equivalents, and marketable securities as of September 30, 2024.

Clinical development and study updates

• Rilparencel, a proprietary autologous cell therapy, is in pivotal Phase 3 development for advanced CKD in type 2 diabetes, with FDA confirming the PROACT 1 trial could support full U.S. approval and accelerated pathway if eGFR slope is used as a surrogate endpoint.

• Phase 2 study 002 showed stabilization of kidney function for up to 30 months in high-risk patients, leading to a protocol amendment for phase 3 to focus on this group.

• Interim results from phase 2/REGEN-007 indicated preserved kidney function for 12–18 months in high-risk patients, with a robust safety profile and no serious adverse events.

• Externally matched controls experienced a continuous decline in kidney function over 18 months, while rilparencel-treated subjects showed stabilization, suggesting potential clinical benefit.

• Phase 3 PROACT 1 is a pivotal, sham-controlled study enrolling over 600 patients with diabetes and CKD (eGFR 20–35), with topline results expected by end of Q3 2027.

Product and mechanism of action insights

• Therapy involves harvesting kidney tissue, expanding primarily tubular and epithelial cells, and injecting them into both kidneys, with dosing based on kidney size.

• Manufacturing improvements have led to a 95%+ success rate in producing viable cells for patients.

• Recent research has improved understanding of cell composition and de-differentiation during manufacturing, with ongoing studies to clarify the mechanism of action.

• Focus remains on autologous kidney cell therapy, with no current plans to expand beyond kidney indications.